PHARMAC - Latest News [Page 1]
Pharmac Seeks Feedback To Fund Medicines For Liver And Ovarian Cancer
Monday, 9 December 2024, 2:05 pm | PHARMAC
The proposal also includes widening access to another medicine, atezolizumab (branded as Tecentriq), which is used with bevacizumab for liver cancer that cannot be removed by surgery. More >>
Update On Oestradiol Patches Supply Issues
Thursday, 28 November 2024, 5:00 pm | PHARMAC
“It’s been very challenging to get an ongoing supply of oestradiol in the midst of a global shortage and we’re hoping that the combination of the oestradiol gel and the new patches will solve the shortages here in New Zealand.” More >>
Pharmac Changes Brand Of Funded Oestradiol Patches
Monday, 25 November 2024, 11:03 am | PHARMAC
The company, Viatris, has been contracted to supply Estradiol TDP Mylan from 1 July 2025, conditional on Viatris gaining full regulatory approval for use in New Zealand. More >>
New Heart Medicine For 18,000 New Zealanders
Tuesday, 12 November 2024, 8:15 pm | PHARMAC
Pharmac funded empagliflozin for the first time in 2020 for some people with type 2 diabetes as it also helps to keep the levels of sugar in the blood in the healthy range. More >>
Pharmac Funds New Medicine And Removes Renewal Criteria For ADHD And Narcolepsy Treatments
Monday, 11 November 2024, 11:16 am | PHARMAC
“We’ve decided to fund lisdexamfetamine, a new stimulant medicine that will provide an additional treatment option for people with ADHD, and we’re also simplifying the renewal process,” says Pharmac’s Chief Medical Officer, Dr David Hughes. More >>
Newly Funded Medicine To Benefit 110 More People With Thyroid, Liver, And Kidney Cancer
Friday, 8 November 2024, 1:49 pm | PHARMAC
Dr David Hughes, Pharmac’s Chief Medical Officer, says feedback on the public consultation helped Pharmac make small changes to the final eligibility criteria for kidney and thyroid cancer to make sure the right people can access treatment. More >>
Pharmac Looks To Fund A Medicine To Keep Bones Strong
Thursday, 31 October 2024, 1:54 pm | PHARMAC
Denosumab stops the body breaking down bones and also removes excess calcium in the blood. More >>
Pharmac Asks For Applications For Medicines For Rare Disorders
Monday, 21 October 2024, 4:08 pm | PHARMAC
“We know that access to effective medicines is an important part of health care for people with rare disorders,” says Dr David Hughes, Pharmac’s Director Advice and Assessment / Chief Medical Officer. More >>
Pharmac Seeking Bids From Suppliers For COVID-19 Vaccines
Thursday, 17 October 2024, 1:12 pm | PHARMAC
“We’re looking at our approach to the funding, eligibility, and procurement of these vaccines to align with other vaccines that we fund and so we can continue keeping New Zealanders well,” says Pharmac’s Chief Executive, Sarah Fitt. More >>
Pharmac Proposing To Fund Low Sensitivity Urine Tests
Tuesday, 15 October 2024, 2:40 pm | PHARMAC
The low sensitivity urine test kit can however detect the levels of hormones in the body through a urine sample done at home and avoid the need for a blood test for some people. More >>
Thousands Benefit From Pharmac Decision To Fund Oestradiol Gel
Thursday, 26 September 2024, 3:07 pm | PHARMAC
Oestradiol is mainly used as a hormone treatment for people whose bodies don’t produce enough oestrogen, usually as a patch placed on the person’s skin. However, global supply issues means that the patches are not always available in New Zealand. More >>
Making More New Cancer Treatments Available For New Zealanders
Wednesday, 18 September 2024, 11:34 am | PHARMAC
“If Pharmac approves funding for these medicines, they have the potential to benefit hundreds of people with cancer,” says Dr David Hughes, Pharmac’s Chief Medical Officer. More >>
5,700 People To Benefit From Widened Access To Funded Medicines
Tuesday, 17 September 2024, 6:48 pm | PHARMAC
These treatments will help people manage the symptoms they experience on a daily basis – supporting their health and wellbeing. The decision includes treatments for schizophrenia, low iron levels, constipation, and severe psoriasis of the genitals ... More >>
First Cancer Medicine Decision Following Pharmac Funding Boost
Monday, 16 September 2024, 2:02 am | PHARMAC
Pharmac will expand access to Pembrolizumab and Nivolumab for various cancers, benefiting thousands and improving patient survival from October and November 2024. More >>
Pharmac To Fund Continuous Glucose Monitors For Thousands Of People With Type 1 Diabetes
Friday, 13 September 2024, 10:36 pm | PHARMAC
About 12,000 people with type 1 diabetes are expected to receive CGMs in the first year of funding, rising to more than 18,000 after five years. There are about 4,800 people currently using insulin pumps and Pharmac expects this number to increase ... More >>
Proposal To Fund Medicines For Lung Cancer, Breast Cancer And Respiratory Conditions
Friday, 13 September 2024, 12:15 pm | PHARMAC
If approved, Pharmac estimates that in the first year of funding about 300 people would benefit from the funding of osimertinib and trastuzumab deruxtecan. More >>
New Medicine And An Easier Renewal Process Proposed For People With ADHD
Thursday, 12 September 2024, 12:23 pm | PHARMAC
Pharmac – Te Pātaka Whaioranga is asking for feedback on two changes for people with attention deficit hyperactivity disorder (ADHD) - a new medicine, and changes to the renewal criteria. Pharmac is proposing: to fund lisdexamfetamine – known ... More >>
Pharmac Proposes To Widen Access To Medicine Used In The Treatment Of Heart Failure
Tuesday, 20 August 2024, 11:41 am | PHARMAC
Pharmac is consulting on plans to widen access to empagliflozin, a medicine used in the treatment of chronic heart failure that would benefit more than 18,000 people in the first year of funding. More >>
Pharmac Indicates Interest In Funding Cancer Treatment Bevacizumab
Friday, 9 August 2024, 10:37 am | PHARMAC
“Today, we have issued a Future Procurement Opportunity (FPO) for the cancer treatment bevacizumab,” says Pharmac’s Chief Medical Officer, Dr David Hughes. More >>
Significant Step Forward Proposed For Bowel Cancer
Monday, 5 August 2024, 11:07 am | PHARMAC
Public consultation has opened on Pharmac’s proposal to fund cetuximab (branded as Erbitux) for a type of bowel cancer where the cancer is located on the left side of the bowel and has spread to other parts of the body. More >>